GE HealthCare began a deal to acquire icometrix, a company that provides artificial intelligence (AI)-powered brain imaging analysis for neurological disorders like Alzheimer’s disease.

icometrix will complement GE HealthCare’s MR-guided AI-assisted scanning expertise with analysis and reporting in neurological disease assessment. GE HealthCare plans to integrate the icometrix icobrain platform with its MRI systems.

icobrain aria features the first U.S. Food and Drug Administration (FDA)-cleared computer-aided detection and diagnosis solution for detecting and quantifying known side effects of amyloid targeting therapies known as Amyloid Related Imaging Abnormalities (ARIA).

MRI tech is used to evaluate treatment eligibility and monitor possible side effects—brain swelling and microbleeds—of amyloid targeting therapies. GE HealthCare President and CEO Roland Rott said the transaction marks a pivotal step in the company’s journey to advance precision care in neurology.

“By integrating icometrix’s AI-powered insights with our advanced imaging technologies, we aim to empower care teams with the clarity and confidence needed to navigate complex neurological conditions,” Rott told the press.

GE HealthCare said its will focus on growing patient access to the icobrain aria solution on all vendor MRI systems through commercial distribution and clinical integration. icobrain aria identifies both forms of ARIA: ARIA-E and ARIA-H from MR scans and performs longitudinal analysis of ARIA occurrence over time. It provides radiologists with tools for monitoring Alzheimer’s patients receiving anti-amyloid therapies over the course of treatment.

“Along with our commitment to pushing the barriers of neuroscience research with our innovative MRI technology, we’re dedicated to strengthening our neurology portfolio and our MR imaging capabilities to provide advanced solutions to clinicians providing more precise care for patients both now and in the future,” said Kelly Londy, president and CEO, MR, GE HealthCare. “Our anticipated acquisition of icometrix and its icobrain solutions supports our goal to help clinicians deliver high-quality, timely care to meet this increased demand in MR technology.”

icometrix’s suite of solutions includes tools that help radiologists compare and quantify brain MR scans over time for disorders ranging from multiple sclerosis, dementia, epilepsy, stroke and traumatic brain injury, among others. The suite also touts a pipeline of clinical decision support applications in development.

“Building on our existing relationship, we are excited by the prospect of joining GE HealthCare and leveraging icometrix’ innovation talents and customer relationships to continue to improve the diagnostic and treatment journey for both neurological clinicians and their patients,” said Wim Van Hecke, icometrix CEO. “Together, we aim to leverage our complementary technology to address the complexities of managing neurological care.”